Edogestrone

Edogestrone
Clinical data
Other names	Edogesterone; PH-218; 17α-Acetoxy-3,3-ethylenedioxy-6-methylpregn-5-en-20-one
Drug class	Progestogen; Progestogen ester
Identifiers
	IUPAC name [(8'R,9'S,10'R,13'S,14'S,17'R)-17'-acetyl-6',10',13'-trimethylspiro[1,3-dioxolane-2,3'-2,4,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene]-17'-yl] acetate;
CAS Number	809-01-8;
PubChem CID	20055315;
ChemSpider	92030;
UNII	9014UFK50C;
CompTox Dashboard (EPA)	DTXSID501024656 ;
Chemical and physical data
Formula	C26H38O5
Molar mass	430.585 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C2CC3(CCC2(C4CCC5(C(C4C1)CCC5(C(=O)C)OC(=O)C)C)C)OCCO3;
	InChI InChI=1S/C26H38O5/c1-16-14-19-20(23(4)10-11-25(15-22(16)23)29-12-13-30-25)6-8-24(5)21(19)7-9-26(24,17(2)27)31-18(3)28/h19-21H,6-15H2,1-5H3/t19-,20+,21+,23-,24+,26+/m1/s1; Key:UOYMGHSCINLOBK-ZKKYLISVSA-N;

Edogestrone (INNTooltip International Nonproprietary Name, BANTooltip British Approved Name) (developmental code name PH-218), or edogesterone, also known as 17α-acetoxy-3,3-ethylenedioxy-6-methylpregn-5-en-20-one, is a steroidal progestin and antiandrogen of the 17α-hydroxyprogesterone group which was synthesized in 1964 but was never marketed.^[1]^[2] Similarly to the structurally related steroid cyproterone acetate, edogestrone binds directly to the androgen receptor and antagonizes it, displacing androgens like testosterone from the receptor, though not as potently as cyproterone acetate.^[3] The drug has also been found to suppress androgen production, likely via progesterone receptor activation-mediated antigonadotropic activity.^[4]